Navigation Links
Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
Date:6/25/2010

encouraged by the preclinical results with anti-GITR immunotherapy. This approach appears to induce unique mechanisms for augmenting antitumor immune responses and holds promise for treating malignancies in man," said Louis Vaickus, MD, Chief Medical Officer at Tolerx. "In a murine model of established colon cancer, the results, especially the complete remissions, were striking and these findings represent preclinical proof of concept for TRX518."

About TRX518

TRX518 is a targeted T-cell immunomodulator that binds to the glucocorticoid-induced tumor necrosis factor receptor (GITR) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the antitumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function and preclinical models suggest TRX518 may have a reduced risk of causing the serious inflammatory side effects that can result from cytokine release.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three preclinical candidates, TRX518, TRX585, and TRX385, which enhance immune responses and as such are being evaluated
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
2. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
10. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National Necrotizing ... Fernando Davila has been successfully treated for a life ... Dr, Anibal R. Gauto , Medical Director of Inpatient ... Eisenhower Medical Center in Rancho Mirage, California ... pioneered by Dr. John Crew at Seton Hospital ...
(Date:8/20/2014)... 2014 Research and Markets  has announced the ... report to their offering. Global Market Report ... Pralmorelin globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... a mastectomy has long been an option, but a new ... it. "The most common reasons women didn,t undergo reconstruction ... in more surgery or they were focused on their cancer ... surgery at Memorial Sloan Kettering Cancer Center, in New York ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... cause of endophthalmitis, a potentially blinding condition that can ... are the well-known staphylococci ("staph") and ... published in the August issue of Ophthalmology ... cases at New York Eye and Ear Infirmary of ... that gram-positive bacteria, which include staph and strep infections, ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... in the search for new Alzheimer,s,drugs, BIRMINGHAM, ... not-for-profit organization that conducts basic and applied,research in ... development --,today announced it has received funding from ... small molecules that activate Nuclear,Factor-kB (NF-kB)--a transcription factor ...
... -, NEW YORK, Oct. 1 American Media, Inc. (AMI) ... Form 10-Q,for the quarterly period ended June 30, 2007. In the ... first quarter of fiscal 2007 were $121.8 million, as ... 2006, representing a 5.6% increase., ...
... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
... 1. Organizations Issue Comprehensive Guidelines for Treating Low Back Pain ... , (Clinical Guidelines, p. 487.) (NOTE: This article is ... A separate news release will be issued.) , ... at Suppressing Hepatitis B Virus , A 52-week, randomized ...
... Flextronics International,Ltd. (Nasdaq: FLEX ) announced ... Corporation (NYSE: SLR ) creating the most ... vertically integrated,electronics manufacturing services ("EMS"). As a ... worldwide,EMS capabilities, from design resources to end-to-end vertically ...
... has named Glenn Adriance as Vice President of ... proven track record of developing, implementing,and managing effective ... "Glenn brings a wealth of experience to ... am pleased to welcome Glenn to the Mesa ...
Cached Medicine News:Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:American Media Operations, Inc. Files Form 10-Q For First Quarter 2007 2Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:Annals of Internal Medicine tip sheet for Oct. 2 2Health News:Flextronics Completes Acquisition of Solectron 2Health News:Flextronics Completes Acquisition of Solectron 3Health News:Flextronics Completes Acquisition of Solectron 4Health News:Flextronics Completes Acquisition of Solectron 5
... the world's first directly illuminated, hand-held ... tradition of bringing superior ophthalmic technology ... keeping with that tradition, Welch Allyn ... Ophthalmoscope. With its newly designed precision ...
... The TOPCON 3D+ ALE-3700/3700PC/3700CF patternless processing system ... frame, quickly, accurately and with the convenience ... the 3D+ FR-20 Frame Reader, advanced processing ... is available with a polycarbonate feature (ALE-3700 ...
Inquire...
... Model II, is very simple to use ... obtained because it is only necessary to ... with internal reading scales then indicating the ... Since displacements between the centers of spectacle ...
Medicine Products: